Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.55 |
| ▸ | TK1 | P04183 | 2/20 | 0.52 |
| ▸ | TK2 | O00142 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329026 | 0.92 | TYMP (0.53) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL15329291 | 0.91 | TYMP (0.58) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL14900650 | 0.90 | TYMP (0.53) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL23306362 | 0.88 | TYMP (0.53) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL20360642 | 0.87 | TYMP (0.54) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL16943184 | 0.87 | TYMP (0.51) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL10267862 | 0.87 | TYMP (0.51) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL768182 | 0.87 | TYMP (0.51) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL13188261 | 0.86 | TYMP (0.50) | TYMPTK1TK2ALDH1A1LMNA | |
| SCHEMBL25751534 | 0.86 | TYMP (0.50) | TYMPTK1TK2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600965-B2 | Modified double stranded oligonucleotide | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2025264546-A1 | LIPID-POLYNUCLEIC ACID CONJUGATE COMPOSITIONS AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-12503699-B2 | Compositions and methods for silencing UGT1a1 gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-23 | — | — | US | disclosed |
| US-12460206-B2 | PCSK9 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20250333737-A1 | 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | disclosed |
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-20250277218-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | BANK OF AMERICA, N.A. | 2025-09-04 | — | — | US | disclosed |
| US-20250270562-A1 | BIS-RNAI COMPOUNDS FOR CNS DELIVERY | BANK OF AMERICA, N.A. | 2025-08-28 | — | — | US | disclosed |
| US-20160145629-A1 | TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-05-26 | — | — | US | disclosed |
| US-20160122759-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-05-05 | — | — | US | disclosed |
| US-20160115476-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160017330-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-20160017335-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2016-01-21 | — | — | US | disclosed |
| US-9133461-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-9127274-B2 | Serpinc1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150111841-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2015-04-23 | — | — | US | disclosed |
| US-20130317081-A1 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2013-11-28 | — | — | US | disclosed |
| US-20130281511-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12416006-B2 | Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof | EIF2AK2, DCLRE1B, DNASE1L3 | TYMP 3675/4885TK1 3649/4885TK2 1879/4885 |
| US-12600965-B2 | Modified double stranded oligonucleotide | NSUN2, EIF2AK2, ADAR | TYMP 597/4885TK1 679/4885TK2 270/4885 |
| US-12460206-B2 | PCSK9 iRNA compositions and methods of use thereof | PCSK9, LDLR, RNASE1 | TYMP 3250/4885TK1 2317/4885TK2 2881/4885 |
| US-20160017335-A1 | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PCSK9, LDLR, RNASE1 | TYMP 3250/4885TK1 2317/4885TK2 2881/4885 |
| US-20160122759-A1 | DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES | ADAR, RNASEH1, NSUN2 | TYMP 824/4885TK1 1040/4885TK2 2554/4885 |
| US-20260035702-A1 | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | PLG, PLAU, PLAUR | TYMP 1408/4885TK1 2292/4885TK2 1834/4885 |
| US-20250277218-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | PCSK9, PCSK7, PCSK6 | TYMP 2773/4885TK1 2615/4885TK2 3150/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | TYMP 1167/4885TK1 1049/4885TK2 1294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.